New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
08:02 EDTCVMCEL-SCI receives $225K NIH research grant
CEL-SCI announced that it has been awarded a Phase I Small Business Innovation Research grant in the amount of $225K from the National Institute of Arthritis Muscoskeletal and Skin Diseases, which is part of the National Institutes of Health. The grant will fund the further development of CEL-SCI’s LEAPS technology as a potential treatment for rheumatoid arthritis. The NIH grant was awarded based on preliminary data by Tibor Glant’s team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental RA when it was administered after the disease was induced in the animals. This data was presented in May 2013 by Daniel Zimmerman, CEL-SCI’s senior vice president of research, cellular immunology, at the symposium on “Therapeutic Approaches to Autoimmunity” during the American Association of Immunologists 100th annual meeting in Honolulu, Hawaii.
News For CVM From The Last 14 Days
Check below for free stories on CVM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
08:46 EDTCVMCEL-SCI says University of Minnesota Masonic Cancer Center joins Phase III trial
Subscribe for More Information
September 3, 2014
08:02 EDTCVMCEL-SCI enrolls 20 patients in August in Phase III trial
CEL-SCI Corporation announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine during August 2014. This brings the total study enrollment to 252 patients. “Given that summer months generally have a slower rate of enrollment for clinical trials, our goal was to maintain the enrollment level compared to the three months prior to the summer. In fact, we did better. We continue to add more centers and countries to the study. As we head into the fall, we believe the pace of patient enrollment will further increase,” stated CEL-SCI CEO Geert Kersten.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use